Stocktoria
Pacira BioSciences, Inc. PCRX
Pacira BioSciences, Inc. (PCRX) earns a Piotroski F-score of 8/9 (strong financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $726.4M at a 1.0% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.94 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 8/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.338 |
| Retained earnings / assets | -0.158 |
| EBIT / assets | 0.015 |
| Equity / liabilities | 1.212 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| PCRX | Pacira BioSciences, Inc. | 8/9 | 3.08 | 141.1 | +3.6% |
| AMPH | Amphastar Pharmaceuticals, Inc. | 6/9 | 4.82 | 9.8 | -1.7% |
| SUPN | SUPERNUS PHARMACEUTICALS, INC. | 3/9 | 5.11 | — | +8.6% |
| EBS | Emergent BioSolutions Inc. | 6/9 | 3.44 | 8.4 | -28.8% |
| CORT | CORCEPT THERAPEUTICS INC | 4/9 | 8.97 | 94.1 | +12.8% |
| KNSA | Kiniksa Pharmaceuticals International, plc | 6/9 | 5.08 | 77.2 | +60.1% |
| RARE | Ultragenyx Pharmaceutical Inc. | 4/9 | -9.61 | — | +20.2% |
About Pacira BioSciences, Inc.
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve. It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like osteoarthritis. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product for use in animals. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Brisbane, California.
FAQ
Is PCRX financially healthy?
Pacira BioSciences, Inc.'s Piotroski F-score is 8/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does PCRX pay a dividend?
No, Pacira BioSciences, Inc. does not currently pay a dividend.
How profitable is PCRX?
In FY2025, Pacira BioSciences, Inc. had a net margin of 1.0% and a return on equity of 1.0%.
Is PCRX overvalued or undervalued?
Pacira BioSciences, Inc. trades at about 148.1× trailing earnings — above its 10-year norm (10-year range 19.8×–1485.5×, median 115.5×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for PCRX?
The average Wall-Street price target for Pacira BioSciences, Inc. is $29.67, about 25.2% above the recent price, from 6 analysts.
Is PCRX a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Pacira BioSciences, Inc.: a Piotroski F-score of 8/9, an Altman Z″ in the safe zone, a P/E of about 141.1×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.